Misplaced Pages

Kanematsu Sugiura: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 20:53, 6 July 2014 editRoger-Pixie (talk | contribs)24 edits added his photo← Previous edit Latest revision as of 10:23, 17 October 2024 edit undoHiruhyoko (talk | contribs)158 editsNo edit summary 
(24 intermediate revisions by 21 users not shown)
Line 1: Line 1:
''' Kanematsu Sugiura''' (1890 &ndash; October 21, 1979 in ], ]) was a ] researcher who spent his career at the ]. A pioneer in cancer research",<ref name=Hutchison1980/> he completed over 250 papers before his death. Sugiura received a number of awards and prizes throughout his life, and retired from the center in 1962.
]


He is perhaps best known for his work on ], a controversial ], which he was convinced had a palliative effect on certain mice tumors. The report that was released by Sugiura of his findings of the experiment are as follows: The results clearly show that Amygdalin (Laetrile) significantly inhibits the appearance of lung metastasis in mice bearing spontaneous mammary tumors and increases significantly the inhibition of the growth of the primary tumors.... Laetrile also seemed to prevent slightly the appearance of new tumors.... The improvement of health and appearance of the treated animals in comparison to controls is always a common observation.... Dr. Sugiura has never observed complete regression of these tumors in all his cosmic experience with other chemotherapeutic agents.<ref name=Hutchison1980>{{cite journal |author=Hutchison DJ |title=Kanematsu Sugiura 1890-1979 |journal=Cancer Res. |volume=40 |issue=7 |pages=2625–6 | date=July 1980 |pmid=6992988 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=6992988}}</ref>
''' Kanematsu Sugiura''' (1890 &ndash; October 21, 1979 in ], ]) was a ] researcher who spent his career at the ]. A pioneer in cancer research",<ref name=Hutchison1980/> he completed over 250 papers before his death. Sugiura received a number of awards and prizes throughout his life, and retired from the center in 1962.

He is perhaps best known for his work on ], a controversial ], which he was convinced had a palliative effect on certain mice tumors.<ref name=Hutchison1980>{{cite journal |author=Hutchison DJ |title=Kanematsu Sugiura 1890-1979 |journal=Cancer Res. |volume=40 |issue=7 |pages=2625–6 | date=July 1980 |pmid=6992988 |doi= |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=6992988}}</ref>


== Laetrile controversy == == Laetrile controversy ==
In 1972, Memorial Sloan-Kettering Cancer Center board member Benno Schmidt convinced the hospital to test laetrile in order to assert its ineffectiveness "with some conviction".<ref name=Wade1977/> Sugiura found that laetrile inhibited ]s in mice, without destroying the ], but in a ] was unable to conclude that laetrile had anticancer activity. In 1972, Memorial Sloan-Kettering Cancer Center board member Benno Schmidt convinced the hospital to test laetrile in order to assert its ineffectiveness "with some conviction".<ref name=Wade1977/> Sugiura found that laetrile inhibited ]s in mice, without destroying the ], but in a ] was unable to conclude that laetrile had anticancer activity.


The initial positive results were not published because, in the words of Chester Stock, Sugiura's supervisor, ''it would have caused all kind of havoc''. Nevertheless, they were leaked in 1973, causing a stir. Consequently laetrile was tested on 14 tumor systems, and a Sloan-Kettering press release concluded that ''laetrile showed no beneficial effects''.<ref name=Wade1977/> The initial positive results were not published because, in the words of Chester Stock, Sugiura's supervisor, "it would have caused all kind of havoc." Nevertheless, they were leaked in 1973, causing a stir. Consequently laetrile was tested on 14 tumor systems, and a Sloan-Kettering press release concluded that laetrile showed no beneficial effects.<ref name=Wade1977/>


Three other researchers were unable to confirm Sugiura's results. Mistakes in the Sloan-Kettering press release were highlighted by a group of laetrile proponents, led by Ralph Moss, former public affairs official of Sloan-Kettering hospital, who was fired when he announced his membership in the group. These mistakes were considered inconsequential, but Nicholas Wade in ''Science'' noted that ''even the appearance of a departure from strict objectivity is unfortunate.''<ref name=Wade1977>{{cite journal |author=Wade N |title=Laetrile at Sloan-Kettering: A Question of Ambiguity |journal=Science |volume=198 |issue=4323 |pages=1231–1234 | date=December 1977 |pmid=17741690 |doi=10.1126/science.198.4323.1231 |url=}}</ref> Three other researchers were unable to confirm Sugiura's results. Mistakes in the Sloan-Kettering press release were highlighted by a group of laetrile proponents, led by ], former public affairs official of Sloan-Kettering hospital, who was fired when he announced his membership in the group. These mistakes were considered inconsequential, but Nicholas Wade in ''Science'' noted that, "even the appearance of a departure from strict objectivity is unfortunate."<ref name=Wade1977>{{cite journal |author=Wade N |title=Laetrile at Sloan-Kettering: A Question of Ambiguity |journal=Science |volume=198 |issue=4323 |pages=1231–1234 | date=December 1977 |pmid=17741690 |doi=10.1126/science.198.4323.1231 |bibcode=1977Sci...198.1231W }}</ref>


The results of all of the studies were published together in the ''Journal of Surgical Oncology''.<ref>Published in '' ''.</ref> The results of all of the studies were published together in the ''Journal of Surgical Oncology''.<ref>Published in '' ''.</ref>

A documentary film by American filmmaker Eric Merola outlining Dr. Kanematsu Sugiura's involvement in the testing of laetrile at Sloan-Kettering called ''Second Opinion: Laetrile At Sloan-Kettering'' is due to be released in theaters across the United States in the Fall of 2014.<ref>Second Opinion: Laetrile At Sloan-Kettering'' ''.</ref>


== References == == References ==
{{reflist}} {{Reflist}}

{{Authority control}}


{{Persondata <!-- Metadata: see ]. -->
| NAME = Sugiura, Kanematsu
| ALTERNATIVE NAMES =
| SHORT DESCRIPTION = Cancer researcher
| DATE OF BIRTH = 1890
| PLACE OF BIRTH =
| DATE OF DEATH = October 21, 1979
| PLACE OF DEATH = ]
}}
{{DEFAULTSORT:Sugiura, Kanematsu}} {{DEFAULTSORT:Sugiura, Kanematsu}}
]
] ]
] ]
]
]

Latest revision as of 10:23, 17 October 2024

Kanematsu Sugiura (1890 – October 21, 1979 in White Plains, New York) was a cancer researcher who spent his career at the Memorial Sloan-Kettering Cancer Center. A pioneer in cancer research", he completed over 250 papers before his death. Sugiura received a number of awards and prizes throughout his life, and retired from the center in 1962.

He is perhaps best known for his work on laetrile, a controversial alternative cancer treatment, which he was convinced had a palliative effect on certain mice tumors. The report that was released by Sugiura of his findings of the experiment are as follows: The results clearly show that Amygdalin (Laetrile) significantly inhibits the appearance of lung metastasis in mice bearing spontaneous mammary tumors and increases significantly the inhibition of the growth of the primary tumors.... Laetrile also seemed to prevent slightly the appearance of new tumors.... The improvement of health and appearance of the treated animals in comparison to controls is always a common observation.... Dr. Sugiura has never observed complete regression of these tumors in all his cosmic experience with other chemotherapeutic agents.

Laetrile controversy

In 1972, Memorial Sloan-Kettering Cancer Center board member Benno Schmidt convinced the hospital to test laetrile in order to assert its ineffectiveness "with some conviction". Sugiura found that laetrile inhibited secondary tumors in mice, without destroying the primary tumor, but in a blind test was unable to conclude that laetrile had anticancer activity.

The initial positive results were not published because, in the words of Chester Stock, Sugiura's supervisor, "it would have caused all kind of havoc." Nevertheless, they were leaked in 1973, causing a stir. Consequently laetrile was tested on 14 tumor systems, and a Sloan-Kettering press release concluded that laetrile showed no beneficial effects.

Three other researchers were unable to confirm Sugiura's results. Mistakes in the Sloan-Kettering press release were highlighted by a group of laetrile proponents, led by Ralph W. Moss, former public affairs official of Sloan-Kettering hospital, who was fired when he announced his membership in the group. These mistakes were considered inconsequential, but Nicholas Wade in Science noted that, "even the appearance of a departure from strict objectivity is unfortunate."

The results of all of the studies were published together in the Journal of Surgical Oncology.

References

  1. ^ Hutchison DJ (July 1980). "Kanematsu Sugiura 1890-1979". Cancer Res. 40 (7): 2625–6. PMID 6992988.
  2. ^ Wade N (December 1977). "Laetrile at Sloan-Kettering: A Question of Ambiguity". Science. 198 (4323): 1231–1234. Bibcode:1977Sci...198.1231W. doi:10.1126/science.198.4323.1231. PMID 17741690.
  3. Published in Journal of Surgical Oncology 10(2).
Categories: